問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chia-Yi Christian Hosptal (在職)

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

陳柏岳
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳柏岳

List

21Cases

2022-11-10 - 2027-11-09

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-09-15 - 2025-10-22

Phase III

Completed
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)

  • Condition/Disease

    overweight and obesity

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2014-12-01 - 2016-12-31

Others

A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    ABX203

Participate Sites
12Sites

Terminated12Sites

2015-09-01 - 2016-08-31

Others

STUDY TO EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS OF ASC16 (RAVIDASVIR) IN COMBINATION WITH RITONAVIR-BOOSTED ASC08 (DANOPREVIR) AND RIBAVIRIN IN TREATMENT-NAIVE NON-CIRRHOTIC TAIWANESE PATIENTS WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1.

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    ASC16 & ASC08

Participate Sites
5Sites

Terminated5Sites

2017-11-01 - 2021-12-31

Others

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment(OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment

  • Condition/Disease

    Chronic viral hepatitis B

  • Test Drug

    Vemlidy Film-coated tablet

Participate Sites
10Sites

Terminated9Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

林俊彥
Linkou Chang Gung Medical Foundation

2017-03-03 - 2023-02-28

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • Condition/Disease

    Nonalcoholic Steatohepatitis(NASH)

  • Test Drug

    Selonsertib

Participate Sites
20Sites

Terminated18Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
11Sites

Terminated11Sites

2016-08-01 - 2019-04-15

Phase II

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus

  • Condition/Disease

    HBV

  • Test Drug

    SB 9200

Participate Sites
5Sites

Terminated5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB